The Defining Moment for Biosimilars: A Critical Year for Competition in the Biologic and Biosimilar Market

2:40 p.m. – 3:25 p.m. (ET)

Millions of Americans receive their health benefits from self-insured employers who bear the brunt of the rising cost of prescription drugs, especially so-called “specialty drugs.” Employers, on average, spend $1,200 per person annually on prescription drugs alone, and the cost is expected to rise. With a bevy of new biosimilar products coming to market in 2023, including long-awaited competition for some of the most costly and highly-utilized specialty drugs, employers are watching the status of competition and formulary design. The increased adoption of biosimilar medicines represents a promising market-based solution that can bring significant savings to large employers, employees, retirees, and families – but will new therapies really lower costs for patients and employers? 

Join us for a panel discussion on the state of biosimilar in the U.S. marketplace, the impacts on plan design, and what other policies are needed to benefit employers, their employees, and families.  

Meet the Panelists